LillyDirect (Zepbound) tirzepatide: November 2026 price and position
As of November 20, 2026, LillyDirect (Zepbound) is a brand route for tirzepatide: Zepbound vials from $299 (Lilly release, November 6, 2026); dose ladder $299 / $399 / $449 (7.5-15 mg with a refill within 45 days, otherwise $499 / $699) carried from October 15 because lilly.com refused automated reads. It sells or prescribes brand medication rather than compounded tirzepatide, so it has no place in this site’s compounded tirzepatide comparison.
Released · Last reviewed · how we verify
Brand prices for comparison
Bought direct, Zepbound vials cost $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg when each refill is within 45 days (otherwise $499 at 7.5 mg and $699 at 10–15 mg); Wegovy pens cost $349 a month and the Wegovy pill $149 to $299 by dose (NovoCare, read November 20, 2026; the Zepbound ladder is carried from October 15 because lilly.com refused automated reads). See the brand price page.
Limitations and what to check before you enroll
Brand Zepbound is FDA-approved. Through LillyDirect (Zepbound) you pay the manufacturer’s self-pay price, or your insurance copay, plus any fee LillyDirect (Zepbound) charges for its own service. Ask for that fee, what it includes and how it renews before you start. A clinician decides whether any GLP-1 is right for you.
Frequently asked
How much does LillyDirect (Zepbound) charge for tirzepatide?
As of November 20, 2026, LillyDirect (Zepbound) is a brand route for tirzepatide: Zepbound vials from $299 (Lilly release, November 6, 2026); dose ladder $299 / $399 / $449 (7.5-15 mg with a refill within 45 days, otherwise $499 / $699) carried from October 15 because lilly.com refused automated reads. It sells or prescribes brand medication rather than compounded tirzepatide, so it has no place in this site’s compounded tirzepatide comparison.
Is LillyDirect (Zepbound)’s tirzepatide FDA-approved?
LillyDirect (Zepbound) is a brand route: the brand medication it offers (Zepbound) is FDA-approved. Compounded tirzepatide from other programs is not FDA-approved and is not the same product.
Where do these LillyDirect (Zepbound) figures come from?
From LillyDirect (Zepbound)’s own page (first-party read, November 20, 2026), converted to an all-in month-to-month figure (medication plus any required recurring fee, before tax). The source link and read date are listed below, and the same figures are in the open dataset.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Lilly and Hims & Hers joint release (November 6, 2026; read November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- LillyDirect (Zepbound) pricing page (refused automated reads on November 20, 2026; the $299 starting price is confirmed by Lilly’s November 6, 2026 release; the dose ladder is carried from October 15)